Table 1 Baseline demographic and clinical parameters
Characteristics | N = 43 |
|---|---|
Age, mean ± SD | 46 ± 13 |
Gender, n (%) | |
Male | 5 (11.63%) |
Female | 38 (88.37%) |
Age at migraine onset (years), mean ± SD | 18.83 ± 10.38 |
Disease duration (years) mean ± SD | 25.76 ± 15.35 |
Concurrent oral preventive treatments, n (%) | 12 (27.91%) |
Monotherapy | 7 (16.28%) |
Polytherapy | 5 (11.63%) |
Headache days/month, mean ± SD | 20.56 ± 7.55 |
Migraine attacks/month, mean ± SD | 18.33 ± 7.15 |
Chronic migraine pts. n (%) | 35 (81.40%) |
Preventive classes failure, mean ± SD | 3.7 ± 0.85 |
Pain intensity (NRS), mean ± SD | 8.95 ± 1.00 |
Attack duration (hours), mean ± SD | 9.03 ± 11.09 |
Whole pain burden, median ± IQR | 400 ± 1953 |
Pain free 2 hours after painkiller intake, n (%) | 25 (58.14%) |
Days with painkiller intake, mean ± SD | 18.40 ± 8.37 |
Painkiller intake/month, mean ± SD | 22.58 ± 12.33 |
MOH, n (%) | 32 (91.43% of chronic migraine patients) |
HIT-6, median ± IQR | 69 ± 9 |
MIDAS, median ± IQR | 90 ± 65 |
MSQ, median ± IQR | 75.71 ± 28.57 |
BDI-II, median ± IQR | 13.5 ± 15 |
HDRS, median ± IQR | 15 ± 10 |
HARS, median ± IQR | 13 ± 9 |
Sleep problem INDEX II, median ± IQR | 30.56 ± 22.22 |
ASC-12, median ± IQR | 6 ± 7 |
PCS, median ± IQR | 36.5 ± 14 |